R Squared Ltd Makes New Investment in Integer Holdings Corporation $ITGR

R Squared Ltd bought a new position in shares of Integer Holdings Corporation (NYSE:ITGR) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 2,960 shares of the medical equipment provider’s stock, valued at approximately $364,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in shares of Integer in the 1st quarter valued at about $17,634,000. Millennium Management LLC grew its holdings in shares of Integer by 2,408.8% in the 1st quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider’s stock valued at $14,531,000 after acquiring an additional 118,224 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Integer by 38.5% in the 2nd quarter. Aberdeen Group plc now owns 319,229 shares of the medical equipment provider’s stock valued at $39,256,000 after acquiring an additional 88,784 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Integer by 40.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 213,741 shares of the medical equipment provider’s stock valued at $25,224,000 after acquiring an additional 61,273 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of Integer in the 2nd quarter valued at about $6,314,000. Institutional investors own 99.29% of the company’s stock.

Integer Trading Down 1.3%

Shares of NYSE:ITGR opened at $72.94 on Friday. The company has a 50-day simple moving average of $103.61 and a 200 day simple moving average of $112.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.18 and a current ratio of 3.71. The company has a market capitalization of $2.56 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 0.58 and a beta of 0.97. Integer Holdings Corporation has a 52-week low of $66.50 and a 52-week high of $146.36.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.11. The firm had revenue of $467.69 million during the quarter, compared to the consensus estimate of $466.45 million. Integer had a net margin of 4.75% and a return on equity of 12.84%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $1.43 earnings per share. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. Sell-side analysts forecast that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Truist Financial decreased their price objective on Integer from $121.00 to $88.00 and set a “buy” rating for the company in a report on Friday. Citigroup cut Integer from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $140.00 to $77.00 in a report on Thursday. Argus downgraded shares of Integer from a “buy” rating to a “hold” rating in a research note on Friday. Raymond James Financial reiterated an “outperform” rating and issued a $95.00 target price (down from $143.00) on shares of Integer in a research note on Friday. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $80.00 target price (down from $132.00) on shares of Integer in a research note on Friday. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Integer has a consensus rating of “Hold” and an average price target of $97.75.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.